Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#21 / 200 Total
CNTX - Context Therapeutics Inc - Stock Price Chart
TickerCNTX [NASD]
CompanyContext Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap27.95MEPS (ttm)-1.50
P/E-EPS this Y13.67%
Forward P/E-EPS next Y10.42%
PEG-EPS past 5Y-26.70%
P/S-EPS next 5Y-
P/B2.35EPS Q/Q-90.31%
Dividend-Sales Q/Q-
Insider Own12.06%Inst Own18.65%
Insider Trans0.00%Inst Trans4.15%
Short Float0.29%EarningsMar 21/b
Analyst Recom1.00Target Price4.00
Avg Volume484.90K52W Range0.47 - 1.69
May-02-24 07:31AM Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76 (GlobeNewswire) +28.68%
07:30AM Context Therapeutics Announces $100 Million Private Placement (GlobeNewswire)
Apr-01-24 07:30AM Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers (GlobeNewswire)
Mar-21-24 01:53PM CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023 (InvestorPlace) -6.96%
07:43AM Context Therapeutics Reports Full Year 2023 Operating and Financial Results (GlobeNewswire)
Nov-09-23 04:15PM Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results (GlobeNewswire)
Oct-31-23 09:00AM Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76 (GlobeNewswire)
Oct-24-23 12:30PM 10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis (ACCESSWIRE) +13.64%
Sep-27-23 09:00AM Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer s (SITC) 38th Annual Meeting (GlobeNewswire) +16.22%
Aug-10-23 02:19PM Context Therapeutics CEO Marty Lehr notes progress towards the clinic with CTIM-76 in 2Q update (News Direct) +10.64%
VINO - Gaucho Group Holdings Inc - Stock Price Chart
TickerVINO [NASD]
CompanyGaucho Group Holdings Inc
CountryUSA
IndustryReal Estate - Diversified
Market Cap3.50MEPS (ttm)-5.71
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y12.64%
P/S1.63EPS next 5Y-
P/B3.70EPS Q/Q50.42%
Dividend-Sales Q/Q42.07%
Insider Own-Inst Own96.35%
Insider Trans-Inst Trans25.60%
Short Float-Earnings-
Analyst Recom1.00Target Price13752.00
Avg Volume17.27K52W Range3.89 - 124.00
May-01-24 09:15AM Gaucho Group Holdings Announces Completion of Reverse Stock Split (ACCESSWIRE) -20.02%
Apr-29-24 09:00AM Gaucho Group Holdings, Inc. Announces Reverse Stock Split (ACCESSWIRE)
Apr-24-24 08:30AM Gaucho Group Holdings Receives Notice from Nasdaq Regarding Continued Listing Requirements (ACCESSWIRE)
Apr-19-24 10:00AM Gaucho Group Holdings Responds to Positive Economic Shifts in Argentina (ACCESSWIRE)
Apr-16-24 08:00PM Gaucho Group Holdings Announces Delay in Annual Report Filing (ACCESSWIRE)
Apr-09-24 08:30AM Gaucho Group Holdings Announces Strategic Measures to Streamline Operations and Cost Efficiencies (ACCESSWIRE) +14.61%
Apr-08-24 05:38PM 13 Best Penny Stocks to Buy According to Billionaire Ken Griffin (Insider Monkey)
Mar-12-24 08:30AM Blending Luxury and Investment: Gaucho Holdings Introduces Innovative Vineyard Home Rental Program (ACCESSWIRE) -6.41%
Mar-05-24 10:00AM Gaucho Group Holdings, Inc. (Nasdaq:VINO) Unveils Enhanced Website for Algodon Wine Estates, Integrating Luxury Real Estate Sales and Resort Bookings (ACCESSWIRE)
Feb-27-24 12:50PM Gaucho Responds to Notice of Default (ACCESSWIRE)
DRVN - Driven Brands Holdings Inc - Stock Price Chart
TickerDRVN [NASD]
CompanyDriven Brands Holdings Inc
CountryUSA
IndustryAuto & Truck Dealerships
Market Cap1.92BEPS (ttm)-4.66
P/E-EPS this Y2.72%
Forward P/E9.29EPS next Y31.78%
PEG-EPS past 5Y-
P/S0.83EPS next 5Y18.20%
P/B2.12EPS Q/Q-84.73%
Dividend-Sales Q/Q1.74%
Insider Own64.67%Inst Own35.24%
Insider Trans0.00%Inst Trans5.41%
Short Float8.46%EarningsMay 02/b
Analyst Recom1.67Target Price17.36
Avg Volume1.24M52W Range10.60 - 30.75
TodayDowngrade JP Morgan Overweight → Neutral $18 → $12.50
Today 03:23AM Driven Brands Holdings Inc (DRVN) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-02-24 10:49PM Q1 2024 Driven Brands Holdings Inc Earnings Call (Thomson Reuters StreetEvents) -20.26%
12:07PM Driven Brands Shares Drop After Q1 Revenue Miss, Resignation of CFO Gary Ferrera (MT Newswires)
09:34AM Driven Brands Holdings Inc (DRVN) Q1 2024 Earnings: Misses on Net Income, Aligns with Revenue ... (GuruFocus.com)
08:25AM Driven Brands Holdings Inc. (DRVN) Surpasses Q1 Earnings Estimates (Zacks)
07:15AM Driven Brands Holdings Inc. Reports First Quarter 2024 Results (Business Wire)
Apr-22-24 04:35PM Driven Brands Holdings Inc. to host first quarter earnings conference call on May 2, 2024 (Business Wire)
Apr-19-24 09:22AM Higher oil prices, shipping disruptions create a double-edged sword for retailers (Yahoo Finance)
Mar-27-24 05:16AM Notice to Long-Term Investors of Driven Brands Holdings Inc. (DRVN) (Newsfile) +5.60%
Mar-05-24 07:30AM Driven Brands to participate in the Bank of America 2024 Consumer & Retail Conference (PR Newswire)
OPI - Office Properties Income Trust - Stock Price Chart
TickerOPI [NASD, RUT]
CompanyOffice Properties Income Trust
CountryUSA
IndustryREIT - Office
Market Cap124.80MEPS (ttm)-1.54
P/E-EPS this Y-40.90%
Forward P/E-EPS next Y-69.06%
PEG-EPS past 5Y-58.38%
P/S0.23EPS next 5Y5.00%
P/B0.10EPS Q/Q-1063.04%
Dividend1.56%Sales Q/Q5.30%
Insider Own2.13%Inst Own66.28%
Insider Trans0.00%Inst Trans-0.16%
Short Float17.22%EarningsMay 01/a
Analyst Recom3.00Target Price5.80
Avg Volume1.27M52W Range1.81 - 8.80
Today 12:24AM Q1 2024 Office Properties Income Trust Earnings Call (Thomson Reuters StreetEvents)
May-01-24 06:55PM Office Properties Income Trust (OPI) Q1 FFO Lag Estimates (Zacks)
04:30PM Office Properties Income Trust Announces Private Exchange Offers Relating to Existing Unsecured Senior Notes (Business Wire)
04:15PM Office Properties Income Trust Announces First Quarter 2024 Results (Business Wire)
Apr-30-24 08:00AM The RMR Group Announces Completion of Unison Elliott Bay Redevelopment (Business Wire)
Apr-16-24 08:00AM The RMR Group Highlights Recent Achievements in 2023 Annual Sustainability Report (Business Wire)
Apr-11-24 08:00AM Office Properties Income Trust Announces Quarterly Dividend on Common Shares (Business Wire) +10.18%
Apr-03-24 08:00AM Office Properties Income Trust First Quarter 2024 Conference Call Scheduled for Thursday, May 2nd (Business Wire)
Mar-27-24 12:30PM 3 REITs Shunned By Wall Street: Any Hope For A Turn-Around? (Benzinga) +8.29%
08:00AM Office Properties Income Trust Earns 2024 ENERGY STAR Partner of the Year Award for the Seventh Consecutive Year (Business Wire)
SYT - SYLA Technologies Co Ltd ADR - Stock Price Chart
TickerSYT [NASD]
CompanySYLA Technologies Co Ltd ADR
CountryJapan
IndustrySoftware - Application
Market Cap88.00MEPS (ttm)-
P/E-EPS this Y-34.92%
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-41.82%
Dividend0.49%Sales Q/Q4.44%
Insider Own-Inst Own0.00%
Insider Trans-Inst Trans-
Short Float-Earnings-
Analyst Recom-Target Price-
Avg Volume216.92K52W Range1.46 - 8.74
May-02-24 09:00AM SYLA Announces Sale of One Building of Its SYFORME Brand Condominium, SYFORME SUMIYOSHI II (GlobeNewswire)
Apr-25-24 09:00AM SYLA Technologies Announces Gain on Sales of Investment Securities (GlobeNewswire)
Apr-11-24 10:00AM CRAIG D. LINDER SELECTED TO 2024 TOP 50 LAWYERS IN AMERICA (PR Newswire)
Apr-01-24 09:00AM SYLA Announces ietty's Membership Has Surpassed 300,000 (GlobeNewswire) -5.18%
Mar-28-24 09:00AM SYLA Technologies Subsidiary SYLA Solar Announces Issuance of Series 1 Unsecured Bonds (GlobeNewswire)
Mar-04-24 04:05PM SYLA Technologies Subsidiary SYLA Solar Announces Comprehensive Business Alliance with LIVE THE CREATIVE (GlobeNewswire)
Jan-31-24 04:30PM SYLA Technologies Announces Its Growth Strategy Centered on Mergers and Acquisitions (GlobeNewswire)
Jan-25-24 09:00AM SYLA Technologies Announces FY2024 Financial Guidance and Upward Revision of FY2023 Dividend Forecast (GlobeNewswire)
Jan-23-24 09:00AM SYLA Technologies Enters into a Capital and Business Alliance Agreement with RIBERESUTE (GlobeNewswire)
Jan-16-24 09:00AM SYLA Sells Four SYFORME Brand Condominiums to a Private Fund Managed by BlackRock's Real Estate Business (GlobeNewswire) -15.77%
MTC - Mmtec Inc - Stock Price Chart
TickerMTC [NASD]
CompanyMmtec Inc
CountryHong Kong
IndustrySoftware - Application
Market Cap493.89MEPS (ttm)-1.00
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y47.61%
P/S153.38EPS next 5Y-
P/B5.89EPS Q/Q49.86%
Dividend-Sales Q/Q289.48%
Insider Own0.18%Inst Own0.11%
Insider Trans0.00%Inst Trans0.29%
Short Float0.12%Earnings-
Analyst Recom-Target Price-
Avg Volume1.67M52W Range0.36 - 4.86
Apr-29-24 09:00AM Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE) +25.00%
Nov-17-23 06:00PM MMTEC, Inc. Announces Half Year 2023 Unaudited Financial Results (PR Newswire)
Nov-09-23 08:52AM 12 Best Day Trading Stocks To Buy (Insider Monkey)
Nov-08-23 05:00PM MMTEC, Inc. Regains Compliance with Nasdaq Minimum Bid Price Deficiency (PR Newswire)
Oct-13-23 07:00PM MMTEC, INC. TO HOLD ITS 2023 ANNUAL MEETING OF SHAREHOLDERS ON NOVEMBER 10, 2023 (PR Newswire) +20.39%
Jun-28-23 09:30AM MMTEC, Inc. Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency (PR Newswire)
Apr-19-23 01:39PM Is MMTec (NASDAQ:MTC) In A Good Position To Invest In Growth? (Simply Wall St.)
Apr-03-23 06:15AM 7 Cheap Stocks That Are Worth Your Attention (InvestorPlace)
Mar-13-23 10:24AM Regional bank stocks continue to see declines amid SVB crash (Yahoo Finance Video) -20.74%
Mar-06-23 06:00PM MMTEC, INC. ANNOUNCES RELOCATION OF OPERTIONS FROM BEIJING TO HONG KONG (PR Newswire)
APVO - Aptevo Therapeutics Inc - Stock Price Chart
TickerAPVO [NASD]
CompanyAptevo Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap1.82MEPS (ttm)-72.07
P/E-EPS this Y-1223.51%
Forward P/E-EPS next Y59.98%
PEG-EPS past 5Y46.80%
P/S-EPS next 5Y-
P/B0.04EPS Q/Q57.76%
Dividend-Sales Q/Q-
Insider Own0.61%Inst Own2.75%
Insider Trans0.00%Inst Trans13.63%
Short Float9.10%EarningsMar 06/b
Analyst Recom1.00Target Price15.25
Avg Volume814.08K52W Range0.67 - 80.96
May-02-24 07:37AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +17.71%
Apr-16-24 12:47PM Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why (Zacks)
Apr-15-24 04:05PM Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering (ACCESSWIRE) -7.35%
Apr-11-24 08:15AM Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today? (InvestorPlace) -60.08%
08:00AM Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering (ACCESSWIRE)
Apr-10-24 09:00AM Aptevo Therapeutics Provides Pipeline Update (ACCESSWIRE) -26.38%
Mar-18-24 06:00AM Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference (ACCESSWIRE) -8.12%
Mar-07-24 08:55AM Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 (ACCESSWIRE)
Mar-05-24 01:51PM APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -8.55%
08:05AM Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update (ACCESSWIRE)
PBM - Psyence Biomedical Ltd. - Stock Price Chart
TickerPBM [NASD]
CompanyPsyence Biomedical Ltd.
CountryCanada
IndustryBiotechnology
Market Cap17.01MEPS (ttm)-0.03
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-413.01%
Dividend-Sales Q/Q-
Insider Own64.90%Inst Own13.83%
Insider Trans0.00%Inst Trans14.99%
Short Float5.15%Earnings-
Analyst Recom-Target Price-
Avg Volume3.74M52W Range0.51 - 14.55
Apr-17-24 08:00AM Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR) (GlobeNewswire)
Apr-16-24 11:01AM Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire) -12.61%
11:01AM Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire)
Apr-08-24 08:00AM Psyence Biomed Partners with Fluence and iNGENu CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire)
08:00AM Psyence Biomed Partners with Fluence and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial (GlobeNewswire)
08:00AM Fluence Partners with Psyence Biomed and iNGEN CRO to Train Research Therapists for Phase IIb Psilocybin Trial (PR Newswire)
Mar-26-24 11:06AM Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business (GlobeNewswire)
Mar-18-24 04:05PM Psyence Biomedical Welcomes Results of a Recent Study Highlighting Benefits of Nature Derived Psilocybin Vs. Synthetic Psilocybin (GlobeNewswire)
Mar-15-24 04:30PM Psyence Biomedical Ltd. Receives Nasdaq Notifications Regarding Market Value of Listed Securities and Market Value of Publicly Held Shares (GlobeNewswire) -18.87%
Mar-12-24 11:15AM Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study (GlobeNewswire) -30.51%
AKTX - Akari Therapeutics Plc ADR - Stock Price Chart
TickerAKTX [NASD]
CompanyAkari Therapeutics Plc ADR
CountryUSA
IndustryBiotechnology
Market Cap9.73MEPS (ttm)-
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q15.04%
Dividend-Sales Q/Q-
Insider Own0.40%Inst Own4.41%
Insider Trans0.00%Inst Trans-
Short Float0.01%EarningsApr 01/b
Analyst Recom1.00Target Price80.00
Avg Volume16.10K52W Range1.08 - 5.50
May-01-24 08:01AM Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics (GlobeNewswire) +10.39%
08:00AM Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity (GlobeNewswire)
Apr-15-24 08:00AM Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024 (GlobeNewswire)
Apr-01-24 06:30AM Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights (GlobeNewswire) -19.03%
Mar-08-24 04:38PM Kuehn Law Encourages VIVK, HES, SDPI, and AKTX Investors to Contact Law Firm (GlobeNewswire)
Mar-05-24 08:00AM Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit (GlobeNewswire)
Jan-02-24 08:00AM Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing (GlobeNewswire) -7.16%
Dec-14-23 08:00AM Akari Therapeutics to Present at Biotech Showcase 2024 (GlobeNewswire) +5.84%
Dec-01-23 08:00AM Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors (GlobeNewswire) +9.49%
Nov-16-23 08:00AM Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference (GlobeNewswire)
ELEV - Elevation Oncology Inc - Stock Price Chart
TickerELEV [NASD]
CompanyElevation Oncology Inc
CountryUSA
IndustryBiotechnology
Market Cap185.84MEPS (ttm)-1.03
P/E-EPS this Y33.58%
Forward P/E-EPS next Y-1.57%
PEG-EPS past 5Y-52.56%
P/S-EPS next 5Y-
P/B2.60EPS Q/Q68.71%
Dividend-Sales Q/Q-
Insider Own21.92%Inst Own66.24%
Insider Trans0.00%Inst Trans-2.99%
Short Float13.03%EarningsMay 02/b
Analyst Recom1.00Target Price7.75
Avg Volume1.03M52W Range0.36 - 5.89
May-02-24 01:54PM ELEV Stock Earnings: Elevation Oncology Misses EPS for Q1 2024 (InvestorPlace)
07:30AM Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements (PR Newswire)
Apr-11-24 06:40AM 7 Top Stocks Under $7 (InvestorPlace) +7.39%
Apr-08-24 04:30PM Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 (PR Newswire) -5.50%
Mar-28-24 01:15PM 13 Hot Stocks to Invest in According to Wall Street Analysts (Insider Monkey)
Mar-07-24 01:54PM Elevation Oncology Inc (ELEV) Reports Financial Results for Q4 and Full Year 2023 (GuruFocus.com)
Mar-06-24 02:51PM ELEV Stock Earnings: Elevation Oncology Beats EPS for Q4 2023 (InvestorPlace)
07:30AM Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements (PR Newswire)
Mar-05-24 06:00PM Trim the Fat: 3 Overbought Stocks Poised for a Pullback (InvestorPlace)
04:50PM Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024 (PR Newswire)
12345678⋯10⋯20
affiliate • advertise • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.